Cosmo Pharmaceuticals N.V. · ISIN: NL0011832936 · EQS - Company News

Cosmo confirms full redemption in cash of €175m Convertible Bonds

Cosmo Pharmaceuticals N.V. / Key word(s): Bond Cosmo confirms full redemption in cash of €175m Convertible Bonds 06.12.2023 / 06:00 GMT/BST Dublin, Ireland – 06 December 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it has fully redeemed all of its EUR 175 million 2.5% Senior Unsecured Convertible Bonds due 2023 in cash. Upcoming Calendar of Events   Preliminary Results 2023 February 15, 2024 Full Year 2023 Results ...

SIX:COPN Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Cosmo Pharmaceuticals N.V.

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (1)
Short Selling (UK) (0)
06 December 2023 07:00AM
Cosmo confirms full redemption in cash of €175m Convertible Bonds
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Bond Cosmo confirms full redemption in cash of €175m Convertible Bonds 06.12.2023 / 06:00 GMT/BST Dublin, Ireland – 06 December 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it has fully redeemed all of its EUR 175 million 2.5% Senior Un...
Cosmo Pharmaceuticals N.V.
About the publication
10 October 2023 07:00AM
Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Regulatory Admission Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA) 10.10.2023 / 06:00 GMT/BST Submission to EMA is supported and based on the efficacy and safety evidence gathered in two identical, randomized, placebo-controlled phase II...
Cosmo Pharmaceuticals N.V.
About the publication
02 October 2023 07:00AM
Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries 02.10.2023 / 06:00 GMT/BST Dublin, Ireland – 02 October 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hikma Pharmaceuticals PLC (LSE:...
Cosmo Pharmaceuticals N.V.
About the publication
27 September 2023 07:00AM
Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa
NL0011832936
Cassiopea, the subsidiary of Cosmo, will be responsible for Centralized Marketing Authorization at European Medicines Agency, while Glenmark will undertake registration of the product in South Africa and in the UK Cassiopea will receive an upfront payment of USD 5 million, in addition to double-digit regulatory and sales milestones as well as agre...
Cosmo Pharmaceuticals N.V.
About the publication
04 September 2023 07:00AM
Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions 04.09.2023 / 06:00 GMT/BST Dublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Adalvo Ltd...
Cosmo Pharmaceuticals N.V.
About the publication
04 September 2023 06:45AM
Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma 04.09.2023 / 05:45 GMT/BST Dublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the termination by mutual agreement of the license...
Cosmo Pharmaceuticals N.V.
About the publication
26 July 2023 06:00AM
Cosmo presents strong H1 2023 operational and financial results
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR  Reaffirmation of FY 2023 guidance of total revenues in the range of €110 million - €120 million and an operating profit in the range of €25 million - €35 million  Repayment of €175m convertible bonds due November 2023 fully in cash at maturity  Dublin, Ireland – 26 July 2023. Cosmo Pharmaceuticals N.V. ...
Cosmo Pharmaceuticals N.V.
About the publication
26 July 2023 06:00AM
Cosmo presents strong H1 2023 operational and financial results
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR  Reaffirmation of FY 2023 guidance of total revenues in the range of €110 million - €120 million and an operating profit in the range of €25 million - €35 million  Repayment of €175m convertible bonds due November 2023 fully in cash at maturity  Dublin, Ireland – 26 July 2023. Cosmo Pharmaceuticals N.V. ...
Cosmo Pharmaceuticals N.V.
About the publication
05 July 2023 07:15AM
Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Half Year Results Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023 05.07.2023 / 06:15 GMT/BST Dublin, Ireland – 5 July 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2023 results on Wed...
Cosmo Pharmaceuticals N.V.
About the publication
05 July 2023 07:15AM
Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Half Year Results Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023 05.07.2023 / 06:15 GMT/BST Dublin, Ireland – 5 July 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2023 results on Wed...
Cosmo Pharmaceuticals N.V.
About the publication
29 June 2023 07:15AM
Cosmo announces the beginning of the phase III trials in males for the treatment of androgenetic alopecia
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Study Cosmo announces the beginning of the phase III trials in males for the treatment of androgenetic alopecia 29.06.2023 / 06:15 GMT/BST Dublin, Ireland – June 29, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the beginning of th...
Cosmo Pharmaceuticals N.V.
About the publication
29 June 2023 07:15AM
Cosmo announces the beginning of the phase III trials in males for the treatment of androgenetic alopecia
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Study Cosmo announces the beginning of the phase III trials in males for the treatment of androgenetic alopecia 29.06.2023 / 06:15 GMT/BST Dublin, Ireland – June 29, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the beginning of th...
Cosmo Pharmaceuticals N.V.
About the publication
28 June 2023 07:15AM
Cosmo announces Cortiment® approval in Japan
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Product Launch Cosmo announces Cortiment® approval in Japan 28.06.2023 / 06:15 GMT/BST Dublin, Ireland – 28 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its partner Ferring Pharmaceuticals (“Ferring”) has received the ap...
Cosmo Pharmaceuticals N.V.
About the publication
28 June 2023 07:15AM
Cosmo announces Cortiment® approval in Japan
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Product Launch Cosmo announces Cortiment® approval in Japan 28.06.2023 / 06:15 GMT/BST Dublin, Ireland – 28 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its partner Ferring Pharmaceuticals (“Ferring”) has received the ap...
Cosmo Pharmaceuticals N.V.
About the publication
22 June 2023 07:15AM
Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea 22.06.2023 / 06:15 GMT/BST Dublin, Ireland & Seoul, Korea – 22 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyundai Pharmaceutical Co., Ltd...
Cosmo Pharmaceuticals N.V.
About the publication
22 June 2023 07:15AM
Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea 22.06.2023 / 06:15 GMT/BST Dublin, Ireland & Seoul, Korea – 22 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyundai Pharmaceutical Co., Ltd...
Cosmo Pharmaceuticals N.V.
About the publication
20 June 2023 07:15AM
Cosmo Pharmaceuticals announces approval of Winlevi® in Canada
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Regulatory Approval Cosmo Pharmaceuticals announces approval of Winlevi® in Canada 20.06.2023 / 06:15 GMT/BST Dublin, Ireland – 20 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its partner Sun Pharmaceutical Industries Limited (Reuters: SUN.B...
Cosmo Pharmaceuticals N.V.
About the publication
20 June 2023 07:15AM
Cosmo Pharmaceuticals announces approval of Winlevi® in Canada
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Regulatory Approval Cosmo Pharmaceuticals announces approval of Winlevi® in Canada 20.06.2023 / 06:15 GMT/BST Dublin, Ireland – 20 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its partner Sun Pharmaceutical Industries Limited (Reuters: SUN.B...
Cosmo Pharmaceuticals N.V.
About the publication
26 May 2023 05:30PM
Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): AGMEGM Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting 26.05.2023 / 16:30 GMT/BST Dublin, Ireland – 26 May 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its shareholders approved all agenda items at today's a...
Cosmo Pharmaceuticals N.V.
About the publication
26 May 2023 05:30PM
Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): AGMEGM Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting 26.05.2023 / 16:30 GMT/BST Dublin, Ireland – 26 May 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its shareholders approved all agenda items at today's a...
Cosmo Pharmaceuticals N.V.
About the publication
30 March 2023 07:00AM
Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings 30.03.2023 / 06:00 GMT/BST Dublin, Ireland – March 30, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the territory expansio...
Cosmo Pharmaceuticals N.V.
About the publication
30 March 2023 07:00AM
Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings 30.03.2023 / 06:00 GMT/BST Dublin, Ireland – March 30, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the territory expansio...
Cosmo Pharmaceuticals N.V.
About the publication
23 March 2023 07:00AM
Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR   Dublin, Ireland – 23 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) reports full-year 2022 financial results for the year ended 31 December 2022.   Financial highlights   In 2022, Cosmo has overtaken the €100 million annual revenue threshold for the first time. Revenues €...
Cosmo Pharmaceuticals N.V.
About the publication
23 March 2023 07:00AM
Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR   Dublin, Ireland – 23 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) reports full-year 2022 financial results for the year ended 31 December 2022.   Financial highlights   In 2022, Cosmo has overtaken the €100 million annual revenue threshold for the first time. Revenues €...
Cosmo Pharmaceuticals N.V.
About the publication
22 March 2023 07:00AM
Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 22 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its fully owned subsidiary Cosmo Intelligent Medical Devices – IMD is expanding its cooperation with Medtronic, the world’s largest healthcare technology provider, to accelerate the developme...
Cosmo Pharmaceuticals N.V.
About the publication
22 March 2023 07:00AM
Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 22 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its fully owned subsidiary Cosmo Intelligent Medical Devices – IMD is expanding its cooperation with Medtronic, the world’s largest healthcare technology provider, to accelerate the developme...
Cosmo Pharmaceuticals N.V.
About the publication
16 March 2023 07:00AM
Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023 16.03.2023 / 06:00 GMT/BST Dublin, Ireland – 16 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its ...
Cosmo Pharmaceuticals N.V.
About the publication
16 March 2023 07:00AM
Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023 16.03.2023 / 06:00 GMT/BST Dublin, Ireland – 16 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its ...
Cosmo Pharmaceuticals N.V.
About the publication
16 February 2023 07:00AM
Cosmo Pharmaceuticals reports record results for 2022, preliminary results exceeding guidance, increased dividend distribution and 2023 guidance
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 16 February 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced its preliminary unaudited results for the financial year 2022. Total revenues of €102.1m vs. guidance of €90m - €100m, representing growth of 56.9% compared to 2021 (€ 65.1m) Operating profit...
Cosmo Pharmaceuticals N.V.
About the publication
16 February 2023 07:00AM
Cosmo Pharmaceuticals reports record results for 2022, preliminary results exceeding guidance, increased dividend distribution and 2023 guidance
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 16 February 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced its preliminary unaudited results for the financial year 2022. Total revenues of €102.1m vs. guidance of €90m - €100m, representing growth of 56.9% compared to 2021 (€ 65.1m) Operating profit...
Cosmo Pharmaceuticals N.V.
About the publication
21 December 2022 07:00AM
Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi® in Southeast Asia
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland & Singapore – 21 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyphens Pharma International Limited (SGX: 1J5) (“Hyphens”) today announced the signing of License and Supply Agreements for Winlevi® (clascoterone) cream 1% in Southeast Asia.  Under the ...
Cosmo Pharmaceuticals N.V.
About the publication
21 December 2022 07:00AM
Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi® in Southeast Asia
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland & Singapore – 21 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyphens Pharma International Limited (SGX: 1J5) (“Hyphens”) today announced the signing of License and Supply Agreements for Winlevi® (clascoterone) cream 1% in Southeast Asia.  Under the ...
Cosmo Pharmaceuticals N.V.
About the publication
14 December 2022 07:00AM
Cosmo announces successful Phase III clinical trial of Lumeblue™ in China
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Study results Cosmo announces successful Phase III clinical trial of Lumeblue™ in China 14.12.2022 / 06:00 GMT/BST   Dublin, Ireland – 14 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful phase III clinical trial of Lumeblue™ in C...
Cosmo Pharmaceuticals N.V.
About the publication
14 December 2022 07:00AM
Cosmo announces successful Phase III clinical trial of Lumeblue™ in China
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Study results Cosmo announces successful Phase III clinical trial of Lumeblue™ in China 14.12.2022 / 06:00 GMT/BST   Dublin, Ireland – 14 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful phase III clinical trial of Lumeblue™ in C...
Cosmo Pharmaceuticals N.V.
About the publication
20 October 2022 07:00AM
Cosmo announces FDA grants orphan-drug designation of rifamycin for treatment of pouchitis
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Regulatory Approval Cosmo announces FDA grants orphan-drug designation of rifamycin for treatment of pouchitis 20.10.2022 / 06:00 GMT/BST Dublin, Ireland – 20 October 2022. Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announces that the FDA has granted the orphan-drug desi...
Cosmo Pharmaceuticals N.V.
About the publication
20 October 2022 07:00AM
Cosmo announces FDA grants orphan-drug designation of rifamycin for treatment of pouchitis
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Regulatory Approval Cosmo announces FDA grants orphan-drug designation of rifamycin for treatment of pouchitis 20.10.2022 / 06:00 GMT/BST Dublin, Ireland – 20 October 2022. Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announces that the FDA has granted the orphan-drug desi...
Cosmo Pharmaceuticals N.V.
About the publication
12 October 2022 07:00AM
GI Genius™ named to FORTUNE 2022 “Change the World” list
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous GI Genius™ named to FORTUNE 2022 “Change the World” list 12.10.2022 / 06:00 GMT/BST Dublin, Ireland – 12 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that Medtronic, its global partner for GI Genius™, published a media release th...
Cosmo Pharmaceuticals N.V.
About the publication
12 October 2022 07:00AM
GI Genius™ named to FORTUNE 2022 “Change the World” list
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous GI Genius™ named to FORTUNE 2022 “Change the World” list 12.10.2022 / 06:00 GMT/BST Dublin, Ireland – 12 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that Medtronic, its global partner for GI Genius™, published a media release th...
Cosmo Pharmaceuticals N.V.
About the publication
06 October 2022 07:15AM
Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening 06.10.2022 / 06:15 GMT/BST Dublin, Ireland – 06 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN...
Cosmo Pharmaceuticals N.V.
About the publication
06 October 2022 07:15AM
Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening
NL0011832936
Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening 06.10.2022 / 06:15 GMT/BST Dublin, Ireland – 06 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN...
Cosmo Pharmaceuticals N.V.
About the publication
04 October 2022 07:00AM
Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement for Winlevi® in Germany, Italy and Austria
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland & Heppenheim, Germany – 04 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and InfectoPharm today announced the signing of a License and Distribution Agreement for Winlevi® (clascoterone) cream 1% in Germany, Italy and Austria.  Under the terms of the agreem...
Cosmo Pharmaceuticals N.V.
About the publication
04 October 2022 07:00AM
Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement for Winlevi® in Germany, Italy and Austria
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland & Heppenheim, Germany – 04 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and InfectoPharm today announced the signing of a License and Distribution Agreement for Winlevi® (clascoterone) cream 1% in Germany, Italy and Austria.  Under the terms of the agreem...
Cosmo Pharmaceuticals N.V.
About the publication
28 July 2022 07:06AM
Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced strong financial half-year 2022 results, with record revenue of €41.5 million up 46.1% (H1 2021: €28.4 million), EBITDA of €14.9 million up 338.2% (H1 2021: €3.4 million), operating profit of €8.1 ...
Cosmo Pharmaceuticals N.V.
About the publication
28 July 2022 07:06AM
Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced strong financial half-year 2022 results, with record revenue of €41.5 million up 46.1% (H1 2021: €28.4 million), EBITDA of €14.9 million up 338.2% (H1 2021: €3.4 million), operating profit of €8.1 ...
Cosmo Pharmaceuticals N.V.
About the publication
28 July 2022 07:01AM
Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR   Dublin, Ireland & Shenyang, China – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and 3SBio (1530.HK) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in Mainland China, Taiwan, Hong Kong and Macao (“Greater China”).   Winlevi® ...
Cosmo Pharmaceuticals N.V.
About the publication
28 July 2022 07:01AM
Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR   Dublin, Ireland & Shenyang, China – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and 3SBio (1530.HK) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in Mainland China, Taiwan, Hong Kong and Macao (“Greater China”).   Winlevi® ...
Cosmo Pharmaceuticals N.V.
About the publication
26 July 2022 07:01AM
Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland and Mumbai, India – 26 July 2022: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) and Cassiopea, a subsidiary of Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43...
Cosmo Pharmaceuticals N.V.
About the publication
26 July 2022 07:01AM
Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia
NL0011832936
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland and Mumbai, India – 26 July 2022: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) and Cassiopea, a subsidiary of Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43...
Cosmo Pharmaceuticals N.V.
About the publication
More Cosmo Pharmaceuticals N.V. related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 1 5th December 2018 BlueCrest Capital Management Limited SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN